Investigational drug · Phase 3
Itepekimab
Also called: REGN3500, SAR440340, Itepekimab SAR440340
Not approved by FDA. In 9 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Chronic Obstructive Pulmonary Disease, Chronic Rhinosinusitis With Nasal Polyps, Bronchiectasis.
Phase 3Last checked: Nov 19, 2026Latest source record: Oct 21, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
9
3 still active
All registered trials
18
Any phase or sponsor naming "Itepekimab"
First trial start
2020
Dec 16, 2020
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Itepekimab", any sponsor or status.
Conditions studied
As listed on its trial records.
- Chronic Obstructive Pulmonary Disease
- Chronic Rhinosinusitis With Nasal Polyps
- Bronchiectasis
- Chronic Rhinosinusitis Without Nasal Polyps
Approved drugs for the same conditions: COPD · Respiratory
Largest trials
Live from ClinicalTrials.gov: studies naming "Itepekimab" as an intervention, largest first.
- Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD)Pivotal-lookingCompleted
SanofiSanofi (SNY)
NCT04751487 · 1,234 participants · Start Feb 12, 2021 · Primary completion Apr 21, 2025
Drug: Itepekimab SAR440340; Placebo · For: Chronic Obstructive Pulmonary Disease
Sites: Phoenix, Arizona; Fresno, California; Palm Springs, California · 238 sites in all
- Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD)Pivotal-lookingCompleted
SanofiSanofi (SNY)
NCT04701983 · 1,127 participants · Start Dec 16, 2020 · Primary completion Apr 11, 2025
Drug: Itepekimab SAR440340; Placebo · For: Chronic Obstructive Pulmonary Disease
Sites: Birmingham, Alabama; Jasper, Alabama; Chandler, Arizona · 232 sites in all
- A Study to Investigate Long-term Safety and Tolerability of Itepekimab in Participants With COPDPivotal-lookingCompleted
SanofiSanofi (SNY)
NCT06208306 · 669 participants · Start Jan 11, 2024 · Primary completion Sep 10, 2026
Drug: Itepekimab (SAR440340); Placebo · For: Chronic Obstructive Pulmonary Disease
Sites: Chandler, Arizona; Tucson, Arizona; La Palma, California · 223 sites in all
- Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of SAR440340 (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)Pivotal-lookingCompleted
SanofiSanofi (SNY)
NCT03546907 · 343 participants · Start Jul 16, 2018 · Primary completion Oct 3, 2019
Drug: SAR440340; Placebo and 4 more · For: Chronic Obstructive Pulmonary Disease
Sites: Los Angeles, California; Riverside, California; Rolling Hills Estates, California · 83 sites in all
- A Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Non-cystic Fibrosis BronchiectasisPivotal-lookingCompleted
SanofiSanofi (SNY)
NCT06280391 · 314 participants · Start Feb 20, 2024 · Primary completion Sep 16, 2025
Drug: Itepekimab (SAR440340); Placebo · For: Bronchiectasis
Sites: Phoenix, Arizona; Los Angeles, California; Westminster, California · 117 sites in all
- Evaluation of SAR440340 and as Combination Therapy With Dupilumab in Moderate-to-Severe Asthma ParticipantsPivotal-lookingCompleted
SanofiSanofi (SNY)
NCT03387852 · 296 participants · Start Mar 12, 2018 · Primary completion Mar 21, 2019
Drug: SAR440340; Dupilumab and 3 more · For: Asthma
Sites: Birmingham, Alabama; Long Beach, California; Los Angeles, California · 71 sites in all
- A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal PolypsPivotal-lookingActive, not recruiting
SanofiSanofi (SNY)
NCT06834347 · 231 participants · Start Feb 12, 2025 · Primary completion Sep 23, 2026
Drug: Itepekimab (SAR440340); Placebo and 1 more · For: Chronic Rhinosinusitis With Nasal Polyps
Sites: Arcadia, California; Los Angeles, California; Newport Beach, California · 121 sites in all
- A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal PolypsPivotal-lookingActive, not recruiting
SanofiSanofi (SNY)
NCT06834360 · 216 participants · Start Feb 6, 2025 · Primary completion Sep 24, 2026
Drug: Itepekimab (SAR440340); Placebo and 1 more · For: Chronic Rhinosinusitis With Nasal Polyps
Sites: Birmingham, Alabama; La Mesa, California; Los Angeles, California · 111 sites in all
- Efficacy and Safety of REGN3500 Monotherapy and Combination of REGN3500 Plus Dupilumab in Adult Patients With Moderate-to-Severe Atopic DermatitisPivotal-lookingTerminated
Regeneron PharmaceuticalsRegeneron (REGN)
NCT03736967 · 206 participants · Start Nov 12, 2018 · Primary completion Mar 13, 2020
Drug: REGN3500; Dupilumab and 2 more · For: Atopic Dermatitis
Sites: Phoenix, Arizona; Fountain Valley, California; Long Beach, California · 66 sites in all
- Efficacy, Safety, and Pharmacokinetic Profiles of REGN3500 Administered to Adult Patients With Moderate-to-Severe Atopic DermatitisPivotal-lookingTerminated
Regeneron PharmaceuticalsRegeneron (REGN)
NCT03738423 · 129 participants · Start Nov 13, 2018 · Primary completion Mar 13, 2020
Drug: REGN3500; REGN3500-Matching Placebo · For: Atopic Dermatitis
Sites: Birmingham, Alabama; Phoenix, Arizona; Scottsdale, Arizona · 89 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Structures of clinical antibodies bound to IL-33 uncover two distinct epitopes underlying differential efficacy.
Chen J, Wang Y, Wang X · MAbs 2026
- Reimagining COPD treatment: are biologics the next frontier?
Rogliani P, De Guido I, Gholamalishahi S, et al. · Expert Opin Pharmacother 2026
- Understanding the roles of interleukin-33: is there promise for therapeutic targeting?
Gao X, Yu Y, Zhong S, et al. · Expert Opin Ther Targets 2026
- Updates in COPD Management: From Inflammatory Pathways to Targeted Therapies.
Raman S, Rahman S, Polverino F, et al. · Eur J Clin Invest 2026
- The dawn of the dual-target era in respiratory disease: promise, pitfalls, and a roadmap for bispecific antibodies.
Cheng Y, Ding J, Li Z, et al. · Front Immunol 2026
- Efficacy of Biologics in Patients with Moderate to Very Severe COPD: A Systematic Review.
Brightling CE, Rabe KF, Singh D, et al. · Int J Chron Obstruct Pulmon Dis 2026
Also in development for Chronic Obstructive Pulmonary Disease
- CM512Phase 39 trials
Keymed Biosciences Co.Ltd · Chronic Rhinosinusitis With Nasal Polyposis, Chronic Spontaneous Urticaria (CSU), Asthma
- LunsekimigSAR443765Phase 39 trials
Sanofi · Asthma, Chronic Obstructive Pulmonary Disease, Chronic Rhinosinusitis With Nasal Polyps
- CM310Phase 35 trials
Keymed Biosciences Co.Ltd · Atopic Dermatitis, Moderate to Severe Asthma, Chronic Obstructive Pulmonary Disease
- TQC2731Phase 35 trials
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. · Asthma, Chronic Obstructive Pulmonary Disease, Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
- VerducatibBI 1291583Phase 34 trials
Boehringer Ingelheim · Bronchiectasis, Chronic Obstructive Pulmonary Disease
- AstegolimabPhase 33 trials
Roche (Genentech) · Chronic Obstructive Pulmonary Disease, Chronic Obstructive Pulmonary Disease (COPD)
- CM326Phase 33 trials
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. · Chronic Obstructive Pulmonary Disease, Chronic Rhinosinusitis With Nasal Polyps, Moderate to Severe Asthma
- TQC3721 forPhase 33 trials
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Chronic Obstructive Pulmonary Disease, Pulmonary Disease, Chronic Obstructive
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Sanofi.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.